Issue 4/2017
Content (23 Articles)
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Thomas B. Karasic, Mark A. Rosen, Peter J. O’Dwyer
Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition
Qiong Yang, Florian Puhm, Michael Freissmuth, Christian Nanoff
Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer
Shengshi Huang, Di Wang, Shu Zhang, Xiaoyan Huang, Dandan Wang, Muhammad Ijaz, Yikang Shi
The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group
Munetaka Takekuma, Keita Mori, Tetsuji Iida, Kazuko Kurihara, Motoaki Saitou, Hideki Tokunaga, Kei Kawana, Masae Ikeda, Toyomi Satoh, Toshiaki Saito, Etsuko Miyagi, Yutaka Nagai, Akiko Furusawa, Yoshiaki Kawano, Kouichiro Kawano, Tsutomu Tabata, Yukinobu Ota, Ryoji Hayase, Mikio Mikami, Toru Sugiyama
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer
Naoki Uemura, Shohei Kikuchi, Yasushi Sato, Hiroyuki Ohnuma, Koichi Okamoto, Hiroshi Miyamoto, Masahiro Hirakawa, Tamotsu Sagawa, Koshi Fujikawa, Yasuo Takahashi, Toshinori Okuda, Shinya Minami, Minoru Takahashi, Tetsuro Okamoto, Kohichi Takada, Koji Miyanisi, Tetsuji Takayama, Junji Kato
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma
Michael A. Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect
Tamás Solymosi, Zsolt Ötvös, Réka Angi, Betti Ordasi, Tamás Jordán, László Molnár, John McDermott, Vanessa Zann, Ann Church, Stuart Mair, Genovéva Filipcsei, Gábor Heltovics, Hristos Glavinas
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review
Jung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kim
Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin
N. Blank, I. Laskov, R. Kessous, L. Kogan, S. Lau, I. A. Sebag, Walter H. Gotlieb, L. Rudski
Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis
Mohamed M. Abdel-Daim, Omnia E. kilany, Hesham A. Khalifa, Amal A. M. Ahmed
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
Richard Markus, Vincent Chow, Zhiying Pan, Vladimir Hanes
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells
Azam Rajabpour, Ali Afgar, Habibollah Mahmoodzadeh, Jalal-e-Din Radfar, Farzad Rajaei, Ladan Teimoori-Toolabi
Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
Katsuki Danno, Taishi Hata, Koki Tamai, Yujiro Fujie, Yoshihito Ide, Ho Min Kim, Tadashi Ohnishi, Shunji Morita, Shinichi Yoshioka, Toshihiro Kudo, Junichi Nishimura, Chu Matsuda, Hiroki Akamatsu, Tsunekazu Mizushima, Riichiro Nezu, Yuichiro Doki, Masaki Mori
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
Keith M. Skubitz, Anne H. Blaes, Suma H. Konety, Gary S. Francis
Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea
Kyong Joo Lee, Jae Hee Cho, Sang Hyub Lee, Si Young Song, Kwang Hyuk Lee, Seok Jeong, Ji Kon Ryu, Sang Myung Woo, Seungmin Bang, Jong Kyun Lee, Tae Hoon Lee, Woo Hyun Paik, Yong Tae Kim, Woo Jin Lee
Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
Shigenori Kadowaki, Toshiki Masuishi, Tetsuya Eto, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Masahiro Tajika, Yasumasa Niwa, Yasushi Yatabe, Kei Muro
Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma
E. Fiedor, E. L. Gregoraszczuk
Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia
Islem Ben Hassine, Hanene Gharbi, Ismail Soltani, Hind Ben Hadj Othman, Ahlem Farrah, Hassiba Amouri, Mouheb Teber, Hela Ghedira, Yosra Ben Youssef, Ines Safra, Salem Abbes, Samia Menif
Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
Nao Tagawa, Erika Sugiyama, Masataka Tajima, Yasutsuna Sasaki, Seigo Nakamura, Hiromi Okuyama, Hisanori Shimizu, Vilasinee Hirunpanich Sato, Tadanori Sasaki, Hitoshi Sato
Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy
Xin-min Zhao, Jing Zhao, Xiang-hua Wu, Zhi-guo Luo, Hui-jie Wang, Hui Yu, Jian-hua Chang, Jia-lei Wang
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
Gayathri Srinivasan, Gurjit Singh Sidhu, Elizabeth A. Williamson, Aruna S. Jaiswal, Nasreen Najmunnisa, Keith Wilcoxen, Dennie Jones, Thomas J. George Jr., Robert Hromas
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer
Laurent Laborde, Fatos Oz, Mitko Ristov, Daniel Guthy, Dario Sterker, Paul McSheehy
Optimism and the continued promise of maintenance chemotherapy
John P. Micha, Bram Goldstein, Maurie Markman